David M. Mott — Executive Chairman at Mersana Therapeutics

Mr. David M. Mott, also known as Dave, is a Partner at New Enterprise Associates. Mr. Mott served as a General Partner of New Enterprise Associates since September 17, 2008, where he led the healthcare investing practice. Mr. Mott is significant executive and has business skills and industry knowledge. Mr. Mott focuses on healthcare and biopharmaceuticals investments and leads the New Enterprise healthcare investing practice. He serves as a Senior Advisor of The Royal Institute of International Affairs. He is Partner and General Partner of New Enterprise Associates 14, L.P. He serves as a Senior Advisor of Chatham House. Mr. Mott served as Head of Healthcare Practice at New Enterprise Associates. He has been the Executive Chairman of Mersana Therapeutics, Inc. since July 2012. He serves as an Executive Chairman of 3-V Biosciences, Inc. He served as the Executive Chairman of Prosensa Holding NV. He served as an Executive Vice President of AstraZeneca PLC since June 2007 until July 2008. He joined MedImmune Inc. in April 1992 as a Vice President with responsibility for business development, strategic planning and investor relations and assumed additional responsibility for the medical and regulatory groups, in 1994. He served as the Chief Executive Officer of MedImmune, LLC (also known as MedImmune Inc.) from October 2000 to July 31, 2008 and served as its President from February 2004 to July 31, 2008. Mr. Mott served as the Chief Financial Officer and Executive Vice President of MedImmune Inc. since March 1995 and served as its President and Chief Operating Officer since November 1995. From 1992 to 2008, he worked at MedImmune Limited which including Chief Operating Officer and Chief Financial Officer. He also served as the Chief Executive Officer and President of MedImmune Limited from June 18, 2007 to July 2008. In 2002, he founded MedImmune Ventures, Inc. and departed in July 2008. Prior to joining MedImmune Inc., he served as a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. At Smith Barney, where he was employed from July 1986 to April 1992, his activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services and medical product and device companies. He served as Vice President of Health Care Investment Banking Group at Citigroup CIB. He has been the Chairman of Tesaro, Inc. since July 2011. He serves as the Chairman of Cydan. He serves as the Board Chair of Vtesse, Inc. He serves as a Member of Advisory Board at Bowside Capital LLC. He serves as the Chairman of Imara, Inc. He has been Chairman of Epizyme, Inc. since April 2016. He has been the Chairman of Ardelyx, Inc. since March 2014. He serves as the Chairman of Supervisory Board at BioMarin Nederland B.V. He served as the Chairman of Conceptis Technologies, Inc. He has been the Chairman of Adaptimmune Therapeutics plc since January 1, 2017 and served as its Vice Chairman from May 2016 to December 1, 2016. He served as Chairman of 3-V Biosciences, Inc. He served as the Chairman of Zyngenia, Inc. from 2009 to 2014. Mr. Mott served as Vice Chairman of MedImmune, LLC from October 1998 to June 1, 2007. He has been Member of Supervisory Board at BioMarin Nederland B.V. since January 25, 2012 and serves as its member of the board of directors. He has been a Director of Edimer Pharmaceuticals Inc. since June 30, 2013 and Clementia Pharmaceuticals Inc. since August 2015. He has been a Non-Executive Director at Complexa, Inc. since July 26, 2017. He serves as a Director of St Albans School and Biotechnology Innovation Organization (a/k/a: Biotechnology Industry Organization (BIO)). He has been Non Executive Director of Adaptimmune Therapeutics plc since February 2015. He has been Non-Executive Director at Nightstar Therapeutics Limited and NightstaRx Limited since August 2015. He has been an Independent Director of Ardelyx, Inc. since March 2009. He has been an Independent Director of Epizyme, Inc. since December 2009. He serves as a Member of Advisory Board at Scripps Translational Science Institute (stsi), Board of Trustees of St. James School and on the Board of Governors of Beauvoir, the National Cathedral Elementary School. He has been a Director of Tesaro, Inc since May 2010 and XTuit Pharmaceuticals, Inc. since June 11, 2015. He served on numerous public and private company boards in the biopharmaceutical industry. He served as a Director of Omthera Pharmaceuticals, Inc. from April 2011 to July 18, 2013. He served as a Director of Zosano Pharma Corporation, MdBio, Inc., and of Maryland Tech Council. He served as a Director of Melinta Therapeutics, Inc. until September 2008 and also served as its Independent Director. He served as a Director of Ambit Pharmaceuticals and Rib-X Pharmaceuticals. He served as a Director of Ambit Biosciences Corporation since November 2007. He served as a Director of MedImmune, LLC from November 1995 to June 1, 2007. He served as a Non-Executive Director of Shire plc from October 31, 2007 to October 30, 2009. Mr. Mott holds BA degree in Economics and Government from Dartmouth College.